Accessibility Menu
Novartis logo

Novartis(NYSE) NVS

Current Price$154.87
Market Cap$283.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+4,644%
5 Year+116%
1 Year+36%
1 Month+1%
Novartis last closing stock price
MetricPriceDate
Last closeUSD 155.012026-07-24
Novartis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.81%USD 153.762026-07-17
1 month+1.23%USD 153.122026-06-24
3 month+6.56%USD 145.472026-04-24
Year to date+15.83%USD 133.832025-12-31
1 year+35.96%USD 114.012025-07-24
3 year+73.23%USD 89.482023-07-25
5 year+115.57%USD 71.912021-07-23
Since inception+4,644.25%USD 3.271991-11-18

Novartis Financials at a Glance

Market Cap

$283.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$55.63B

Net Income (TTM)

$12.76B

EPS (TTM)

$6.63

P/E Ratio

23.25

Dividend

$4.74

Beta (Volatility)

0.33 (Low)

Price

$154.87

Volume

90

Open

$155.95

Previous Close

$154.87

Daily Range

$154.46 - $156.41

52-Week Range

$112.34 - $170.46

Estimated Earnings Date

Oct 27, 2026

NVS: Motley Fool Moneyball Superscore

82

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novartis

Novartis AG is a global healthcare company focused on developing, manufacturing, and marketing innovative healthcare products. The company specializes in prescription medicines, particularly in oncology, immunology, neuroscience, and cardiovascular diseases, while also offering a range of established brands and specialized therapies.

Products and Services
  • Innovative prescription medicines in oncology and immunology
  • Specialized therapies for neurological and cardiovascular conditions
  • Established older brands in various therapeutic areas
Growth Outlook
  • Revenue of $13.52 billion in Q1 2026, showing strong demand
  • Net income of $3.16 billion in Q1 2026, reflecting robust profitability
  • Consistent R&D investment, exceeding $2.74 billion in Q1 2026
Financial Highlights
  • Trailing twelve months (TTM) revenue of $54.5 billion, indicating steady growth
  • Net profit margin of 24.31% TTM, showcasing operational efficiency
  • Dividend yield of 2.96%, providing attractive returns to shareholders
Novartis AG stands out in the healthcare sector due to its commitment to innovation and extensive product portfolio. The company's recent financial performance highlights its ability to generate substantial revenue and maintain strong profitability, making it an appealing option for potential investors. The focus on research and development ensures that Novartis remains at the forefront of medical advancements, positioning the company for continued growth in the evolving healthcare landscape.
AI Generated • Jul 19, 2026

Industry

Pharmaceuticals

Employees

75,267

CEO

Vasant Narasimhan, MD

Headquarters

Basel, BS 4056, CH

NVS Financials

Key Financial Metrics (TTM)

Gross Margin

74.29%

Operating Margin

29.86%

Net Income Margin

23.09%

Return on Equity

29.64%

Return on Capital

20.53%

Return on Assets

10.34%

Earnings Yield

4.30%

Dividend Yield

3.06%

Payout Ratio

67.77%

Stock Overview

Market Cap

$283.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.83B

Volume

90

Avg. Volume

1.83M

Financials (TTM)

Gross Profit

$41.41B

Operating Income

$16.99B

EBITDA

$22.26B

Operating Cash Flow

$18.39B

Capital Expenditure

-$2.57B

Free Cash Flow

$15.82B

Cash & ST Invst.

$7.69B

Total Debt

$49.01B

Novartis Performance Analysis

Novartis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 42,288,270,587-18.1%
20232023-12-31USD 45,602,599,2897.8%
20242024-12-31USD 50,288,540,49010.3%
20252025-12-31USD 54,811,252,2069.0%
Novartis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-29-3.2%
Q42025-12-31-7.1%
Q12026-03-311.4%
Q22026-06-306.6%
Novartis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.17-70.1%
20232023-12-31USD 7.12124.6%
20242024-12-31USD 5.86-17.7%
20252025-12-31USD 7.1922.6%
Novartis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-29-1.9%
Q42025-12-31-38.1%
Q12026-03-3132.0%
Q22026-06-303.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$14.42B

-2.8%

Gross Profit

$10.74B

-6.7%

Gross Margin

74.47%

N/A

Market Cap

$283.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.77M

N/A

Employees

75,267

N/A

Net Income

$3.27B

-19.2%

EBITDA

$5.94B

-2.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.69B

+9.9%

Total Debt

$49.01B

+50.2%

Accounts Receivable

$9.85B

+7.4%

Inventory

$6.22B

-1.4%

Long Term Debt

$39.15B

+62.7%

Short Term Debt

$9.86B

+15.0%

Return on Assets

10.34%

N/A

Return on Invested Capital

18.07%

N/A

Free Cash Flow

$5.57B

-8.8%

Operating Cash Flow

$5.89B

-11.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRKMerck & Co., Inc.
$131.07+0.45%
RHHBYRoche Holding AG
$54.70+1.28%
GILDGilead Sciences, Inc.
$129.31-1.18%
PFEPfizer Inc.
$24.54-1.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
NOKNokia
$9.10-0.06%
STAKStak
$9.27+6.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$31.27-0.14%

Questions About NVS

What is the current price of Novartis?

Novartis is trading at $154.87 per share.

What is the 52-week range for Novartis?

Over the past 52 weeks, Novartis has traded between $112.34 and $170.46.

How much debt does Novartis have?

As of the most recent reporting period, Novartis reported total debt of $49.01B.

How much cash does Novartis have on hand?

Novartis reported $7.62B in cash and cash equivalents in its most recent financial results.

What is Novartis’s dividend yield?

Novartis currently has a dividend yield of 3.06%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.